Showing results (171-180 of 969) with videos related to
Sort By:
Pageof 97
Expert Opinion on Investigational Drugs|June 4, 2011
A potential role of ruxolitinib in leukemiaKiran Naqvi, Srdan Verstovsek, Hagop Kantarjian, et al.Cancer|February 15, 2011
FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?Naveen Pemmaraju, Hagop Kantarjian, Farhad Ravandi, et al.Current Hematologic Malignancy Reports|April 29, 2010
Modern treatment programs for adults with acute lymphoblastic leukemiaFarhad Ravandi, Stefan Faderl, Partow Kebriaei, et al.Journal of Hematology|May 15, 2023
Neutropenic Enterocolitis: An Uncommon, but Fearsome Complication of LeukemiaRodrick Babakhanlou, Farhad Ravandi-Kashani, Dimitrios P KontoyiannisAmerican Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 2, 2016
Evolving Therapies in Acute Myeloid Leukemia: Progress at Last?Daniel J DeAngelo, Eytan M Stein, Farhad RavandiCancer|January 28, 2004
New agents in acute myeloid leukemia and other myeloid disordersFarhad Ravandi, Hagop Kantarjian, Francis Giles, et al.Expert Review of Clinical Pharmacology|March 30, 2026
Pharmacokinetics, efficacy, and safety of arsenic formulations in acute promyelocytic leukemia treatmentJennifer Marvin-Peek, Wei-Ying Jen, Farhad RavandiLeukemia Research|June 14, 2003
Chronic lymphocytic leukemia (B-CLL) occurring with human immunodeficiency virus (HIV) infection: implicationsFarhad Ravandi, Amit Verma, Jean Ridgeway, et al.Expert Opinion on Emerging Drugs|March 23, 2011
Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemiaHillary Prescott, Hagop Kantarjian, Jorge Cortes, et al.Blood Advances|June 14, 2018
Evaluating measurable residual disease in acute myeloid leukemiaFarhad Ravandi, Roland B Walter, Sylvie D FreemanPageof 97